ArticleDermatology practical & conceptual2022

Efficacy and Safety of Ixekizumab Versus Adalimumab in Biologic-naïve Patients With Active Psoriatic Arthritis and Moderate-to-severe Psoriasis: 52-week Results From the Randomized SPIRIT-H2H Trial.

Kristian Reich et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.